BioSpace News Archive

Alimera Sciences, Inc. today announced its acquisition of additional commercialization rights for YUTIQ (fluocinolone acetonide intravitreal insert) 0.18mg for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye from EyePoint Pharmaceuticals, Inc. (EyePoint).

Prelude Therapeutics Incorporated today announced the pricing of its underwritten public offering of 3,048,522 shares of its voting common stock and 1,448,222 shares of its non-voting common stock, each at a price to the public of $5.75 per share, and, in lieu of common stock to investors who so choose.

Gossamer Bio, Inc. today announced data from its Phase 2 TORREY Study of seralutinib in patients with PAH will be featured in two sessions at the American Thoracic Society 2023 International Conference taking place in Washington D.C. from May 19-24.

Impulse Dynamics plc announced the completion of the first implantation for the INTEGRA-D clinical trial, designed to evaluate the safety and efficacy of two proven cardiac therapies combined — CCM ® and an implantable cardioverter defibrillator (ICD) — in a single device (CCM-D).

Affinia Therapeutics today announced the presentation of new preclinical data on novel AAV capsids for skeletal muscle, cardiac muscle, and central nervous system (CNS).

Replay, a genome writing company reprogramming biology by writing and delivering big DNA, announced the appointment of Arun Balakumaran, M.D., Ph.D., as Chief Medical Officer, effective 22 May.

VYNE Therapeutics Inc. announced that members of management will attend the Biotechnology Innovation Organization International Convention, taking place June 5-8, 2023 at the Boston Convention & Exhibition Center in Boston, Massachusetts.

Outpace Bio today announced it will present advancements to its OutSmartTM platform during a poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual meeting being held from May 16-20, 2023 in Los Angeles, CA.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced that management will participate in A.G.P.’s Virtual Healthcare Conference on Wednesday, May 24, 2023.

HTG Molecular Diagnostics, Inc. announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 Biotechnology Innovation Organization International Convention and will host in-person meetings during the remaining days of the June 5 – 8, 2023 event in Boston, MA.